Formulation and Evaluation of Zidovudine Matrix Tablets Using Dikamali
نویسنده
چکیده
The aim of the present study is to evaluate the gum Dikamali as a sustained release polymer employing zidovudine as a model drug. Natural gums are economic, easily available and found useful as Pharmaceutical excipients. To the best of our knowledge, no significant work has been reported on dikamali. Zidovudine was received as a gift sample from Hetero Drugs Private limited (Jeedimetla, Hyderabad), Dikamali was received as a gift sample from Girijen Co-operative Corporation (Vishakapatnam). All the other chemicals used for the study are of Commercial grade. Zidovudine Matrix Tablets were prepared by Direct compression technique using dikamali. The prepared tablets were evaluated for Tapped density, Bulk density, Compressibility index, Hausner ratio, Angle of repose, Hardness, Friability, Weight variation, Thickness, Content uniformity. All the parameters were found to be within the limits. Dissolution studies performed for 10 different formulations containing Dikamali as a sustained release polymer in different concentrations like 10%, 15%, 20%, 25%, 30% with and without disintegrant. These Studies revealed that Dikamali at 30% concentration with disintegrant shows better sustaining property. The optimized formulation also subjected to different Kinetic models and it was shown that the formulation follows Higuchi model and from that it was concluded that the rate controlling mechanism is Diffusion. From the Korsmeyer Peppas equation it was found that drug release follows super case II transport. Future scope of this project is to use Dikamali as a binder for preparation of Zidovudine sustain release tablets
منابع مشابه
Design and in vitro evaluation of zidovudine oral controlled release tablets prepared using hydroxypropyl methylcellulose.
Oral controlled release matrix tablets of zidovudine were prepared using different proportions and different viscosity grades of hydroxypropyl methylcellulose. The effect of various formulation factors like polymer proportion, polymer viscosity and compression force on the in vitro release of drug were studied. In vitro release studies were carried out using United States Pharmacopeia (USP) typ...
متن کاملFormulation and Evaluation of Taste Masked Dispersible Tablets of Zidovudine
Zidovudine is an antiretroviral drug commonly used in the treatment HIV infection. But it is very bitter in taste and sparingly soluble in water. Thus the purpose of this investigation was to formulate and evaluate taste masked dispersible tablets of zidovudine. Dispersible tablets of zidovudine were prepared using crosscarmellose sodium (Ac-di-sol) as disintegrant. Surelease clear (E-7-19010) ...
متن کاملFormulation, release and stability study of Bupropion sustained release 150 mg using Hydroxypropylmethylcellulose (HPMC) 4000cps basis
In this study,formulation of sustained-releasingmatrix tablet of bupropion 150 mg, using hydroxypropylmethylcellu lose(HPMC) 4000cps was evaluatedwith the aim of reducing the frequency of daily dose. The level of HPMC4000 ,polyvinylpyrolidone(PVP) and magnesium stearate(Mg St)was varied based on a 2level 3 factor factorial experimental designusing the release rate of the drug from the matrices ...
متن کاملSingle Layer Extended Release Two-In-One Guaifenesin Matrix Tablet: Formulation Method, Optimization, Release Kinetics Evaluation and Its Comparison with Mucinex® Using Box-Behnken Design
Guaifenesin, a highly water-soluble active (50 mg/mL), classified as a BCS class I drug.Owing to its poor flowability and compressibility, formulating tablets especially high-dose one,may be a challenge. Direct compression may not be feasible. Bilayer tablet technology appliedto Mucinex®, endures challenges to deliver a robust formulation. To overcome challengesinvolved in bilayer-tablet manufa...
متن کاملSingle Layer Extended Release Two-In-One Guaifenesin Matrix Tablet: Formulation Method, Optimization, Release Kinetics Evaluation and Its Comparison with Mucinex® Using Box-Behnken Design
Guaifenesin, a highly water-soluble active (50 mg/mL), classified as a BCS class I drug.Owing to its poor flowability and compressibility, formulating tablets especially high-dose one,may be a challenge. Direct compression may not be feasible. Bilayer tablet technology appliedto Mucinex®, endures challenges to deliver a robust formulation. To overcome challengesinvolved in bilayer-tablet manufa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013